Strong claims about the effectiveness of drugs are nothing new. But, on 13 January 2020, at the JP Morgan annual healthcare conference in San Francisco, California, the NHS announced its intent to pursue an agreement with Novartis for its product inclisiran, an injectable, cholesterol-lowering drug given every six months. Lord David Prior — then chair … Continue reading Inclisiran: the ‘extremely unusual’ political influence behind the novel drug’s approval